Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Verzenio looks set to move into a valuable adjuvant setting as Pfizer’s miss with Ibrance is laid bare.
A miss for Roche’s Akt inhibitor in advanced breast cancer leaves questions over population and combination.
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.